This 3M Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Analysts upgraded First Financial, 3M, Synopsys, Humana and Stem, raising targets for four while maintaining Stem’s $7 target.
Stocks · News reference
Stem Affirms FY2026 Sales Guidance of $140.000M-$190.000M vs $160.232M Est
Stem (NYSE:STEM) affirms FY2026 sales outlook from $140.000 million-$190.000 million to $140.000 million-$190.000 million vs $160.232 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Stem shares are trading higher after UBS upgraded the stock from Neutral to Buy rating and maintained the price target at $7.
UBS Upgrades Stem to Buy, Maintains Price Target to $7
UBS analyst Jon Windham upgrades Stem (NYSE:STEM) from Neutral to Buy and maintains the price target from $7 to $7.
UBS Maintains Neutral on Stem, Lowers Price Target to $7
UBS analyst Jon Windham maintains Stem (NYSE:STEM) with a Neutral and lowers the price target from $10.5 to $7.